Quassin (Quassinoid)

Quassin is a bitter quassinoid compound extracted from Quassia amara wood that demonstrates selective anti-cancer properties in preclinical studies. This bioactive compound targets cancer cells with 10-fold greater potency than normal cells through multiple cytotoxic mechanisms.

Origin & History

Quassinoids, including the prototypical compound quassin, are highly oxygenated degraded triterpenoid lactones found exclusively in plants of the Simaroubaceae family, such as Eurycoma longifolia, Picrasma quassioides, and Quassia species. First described in the 19th century and structurally elucidated in 1961, over 150-190 distinct quassinoid structures have been identified through standard phytochemical extraction methods.

Historical & Cultural Context

Quassinoids from Simaroubaceae plants have been used in folk medicine for many years, though specific traditional applications are not well-documented. Eurycoma longifolia has been traditionally used for testosterone enhancement, interestingly contrasting with observed anti-androgenic mechanisms in modern research.

Health Benefits

• Anti-cancer effects demonstrated in preclinical models, with selective cytotoxicity to cancer cells (IC50 5.97 μg/mL) versus normal cells (IC50 59.26 μg/mL) - evidence from in vitro and animal studies only
• Tumor growth suppression shown in xenograft models at 5-10 mg/kg doses against prostate cancer - preliminary animal evidence
• Anti-malarial activity through dihydrofolate reductase (DHFR) binding (Ki 0.095-1.71 μM) - in vitro evidence only
• Neuroprotective effects via reduced caspase-3 activation and apoptosis suppression in oxidative stress models - preliminary in vitro evidence
• Cell cycle arrest and apoptosis induction through multiple pathways including HIF-1α and MYC signaling inhibition - mechanistic studies only

How It Works

Quassin exerts selective cytotoxicity through inhibition of protein synthesis and disruption of mitochondrial function in cancer cells. The compound interferes with ribosomal RNA processing and induces apoptosis via caspase activation pathways. Its preferential targeting of malignant cells appears related to altered metabolic profiles in cancer versus normal tissue.

Scientific Research

No human clinical trials specific to quassin or quassinoids are available in the research literature. The quassinoid bruceantin advanced to two phase II clinical trials for leukemia in 1982 and 1983, though no detailed outcomes or PMIDs are provided. Current evidence is limited to preclinical in vitro and animal model studies.

Clinical Summary

Current evidence for quassin is limited to preclinical in vitro and animal studies. Cell culture studies show IC50 values of 5.97 μg/mL against cancer cells versus 59.26 μg/mL for normal cells, indicating 10-fold selectivity. Xenograft studies in mice demonstrated tumor growth suppression at doses of 5-10 mg/kg against prostate cancer models. No human clinical trials have been conducted to establish safety or efficacy in cancer patients.

Nutritional Profile

Quassin is a pure isolated quassinoid compound (a highly oxygenated tetracyclic diterpene lactone), not a whole food or nutritional ingredient, and therefore contains no macronutrients (zero protein, fat, or carbohydrates), no dietary fiber, no vitamins, and no minerals in any relevant sense. It is used exclusively as a bioactive compound at microgram-to-milligram doses. Key chemical identity: molecular formula C22H28O10, molecular weight ~456.45 g/mol. It is the most bitter naturally occurring compound known, with a bitterness threshold detectable at approximately 0.0000001 g/mL (0.1 ppb). Bioactive concentration context: cytotoxic IC50 against cancer cells reported at 5.97 μg/mL in vitro; anti-malarial activity observed at low micromolar concentrations via DHFR inhibition; insecticidal and antifeedant activity documented at <10 ppm. Naturally sourced from the heartwood and bark of Quassia amara and Picrasma excelsa (quassia wood), where quassin content ranges approximately 0.1–0.2% dry weight of the wood. Bioavailability: lipophilic in character with moderate solubility in ethanol and organic solvents; limited aqueous solubility may restrict oral bioavailability, though specific human pharmacokinetic data (Cmax, half-life, bioavailability %) are not yet established in published literature. No dietary reference intake (DRI) or recommended daily intake exists.

Preparation & Dosage

No clinically studied dosage ranges for human use have been established. Preclinical animal studies used 5-10 mg/kg intraperitoneal injection for anti-tumor effects. Human dosing, standardization details, and oral formulations have not been studied. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other quassinoids (bruceantin, eurycomanone), anti-malarial herbs, bitter digestive compounds, selective anti-cancer botanicals

Safety & Interactions

Safety data for quassin in humans is extremely limited due to lack of clinical studies. As a bitter compound from Quassia amara, potential gastrointestinal irritation and nausea may occur at higher doses. Drug interactions are unknown but possible given its bioactive nature and potential effects on liver enzymes. Pregnancy and lactation safety has not been established, and use should be avoided without medical supervision.